Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa

Reuters

Aug 19

Aldeyra <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Receives FDA <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation for ADX-2191 in Treating Retinitis Pigmentosa

Aldeyra Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug ADX-2191, intended for the treatment of retinitis pigmentosa. This designation is set to expedite the development and review process of ADX-2191, which has shown promising results in a Phase 2 clinical trial by improving retinal sensitivity. Retinitis pigmentosa, a severe genetic eye disease, currently lacks approved therapies for most forms. The Fast Track Designation, along with a previously announced Orphan Drug Designation, highlights the potential of ADX-2191 to meet a significant unmet need in ophthalmology. A Phase 2/3 clinical trial is anticipated to begin in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819317013) on August 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560933591"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560933591\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560933591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560933591","market":"nz","top_or_hot":-1,"title":"Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Receives FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation for ADX-2191 in Treating Retinitis Pigmentosa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a>. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug ADX-2191, intended for the treatment of retinitis pigmentosa. This designation is set to expedite the development and review process of ADX-2191, which has shown promising results in a Phase 2 clinical trial by improving retinal sensitivity. Retinitis pigmentosa, a severe genetic eye disease, currently lacks approved therapies for most forms. The Fast Track Designation, along with a previously announced Orphan Drug Designation, highlights the potential of ADX-2191 to meet a significant unmet need in ophthalmology. A Phase 2/3 clinical trial is anticipated to begin in 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819317013) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Receives FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation for ADX-2191 in Treating Retinitis Pigmentosa\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a>. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug ADX-2191, intended for the treatment of retinitis pigmentosa. This designation is set to expedite the development and review process of ADX-2191, which has shown promising results in a Phase 2 clinical trial by improving retinal sensitivity. Retinitis pigmentosa, a severe genetic eye disease, currently lacks approved therapies for most forms. The Fast Track Designation, along with a previously announced Orphan Drug Designation, highlights the potential of ADX-2191 to meet a significant unmet need in ophthalmology. A Phase 2/3 clinical trial is anticipated to begin in 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819317013) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALDX","symbol_name":"Aldeyra Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDLc8nP6Q:1","article_id":"2560933591","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560933591","pubTimestamp":1755601298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aldeyra Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has granted Fast Track Designation for its drug ADX-2191, intended for the treatment of retinitis pigmentosa. This designation is set to expedite the development and review process of ADX-2191, which has shown promising results in a Phase 2 clinical trial by improving retinal sensitivity. Retinitis pigmentosa, a severe genetic eye disease, currently lacks approved therapies for most forms. The Fast Track Designation, along with a previously announced Orphan Drug Designation, highlights the potential of ADX-2191 to meet a significant unmet need in ophthalmology. A Phase 2/3 clinical trial is anticipated to begin in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Aldeyra Therapeutics ADX-2191治疗视网膜色素变性获得FDA快速通道指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9},"content_text":"Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa\n    \n\nAldeyra Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug ADX-2191, intended for the treatment of retinitis pigmentosa. This designation is set to expedite the development and review process of ADX-2191, which has shown promising results in a Phase 2 clinical trial by improving retinal sensitivity. Retinitis pigmentosa, a severe genetic eye disease, currently lacks approved therapies for most forms. The Fast Track Designation, along with a previously announced Orphan Drug Designation, highlights the potential of ADX-2191 to meet a significant unmet need in ophthalmology. A Phase 2/3 clinical trial is anticipated to begin in 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819317013) on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}